Hard to Treat Diseases Inc.Share · US41164A1034 (OTC) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of Hard to Treat Diseases Inc.
No Price
Closing Price OTC 30.04.2026:
0,00002 USD
30.04.2026 20:00
Current Prices from Hard to Treat Diseases Inc.
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
UTC
HTDS
USD
30.04.2026 20:00
0,00002 USD
-
Company Profile for Hard to Treat Diseases Inc. Share
Hard to Treat Diseases Inc. manufactures, supplies, and exports biopharmaceuticals and vaccines in China and internationally. The company offers biologicals, including reteplase (rPA), mycobacterium vaccae, acutobin urinary kallidinogenase, ulinastatin, and cerebroprotein hydrolysate for injection; chemicals, such as cobratide injection, entecavir capsule, HES, dasatinib tablets, thymosin a1 for injection, imipenem and cilastatin sodium for injection, and meropenem for injection; and vaccines, which include rabies vaccine, ACYW135 meningococcal vaccine, influenza vaccine, Hepatitis A, and varicella vaccine. It markets its products through a sales network that focuses on South Asia, South-east Asia, Central and South America, and the Middle East. Hard to Treat Diseases Inc. was founded in 2009 and is based in Shenzhen, China.
